MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more
MEMPHASYS LTD (IG7) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MEMPHASYS LTD (IG7) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MEMPHASYS LTD - Net Assets Trend (None–None)
This chart illustrates how MEMPHASYS LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MEMPHASYS LTD (None–None)
The table below shows the annual net assets of MEMPHASYS LTD from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MEMPHASYS LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MEMPHASYS LTD Competitors by Market Cap
The table below lists competitors of MEMPHASYS LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REEGF
OTCGREY:REEGF
|
$1.96 Million |
|
TIALIS ESSENTIAL IT PLC
F:U6M
|
$1.96 Million |
|
SWS Capital Bhd
KLSE:7186
|
$1.96 Million |
|
GVP Infotech Limited
NSE:GVPTECH
|
$1.96 Million |
|
Dolphin International Bhd
KLSE:5265
|
$1.96 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
$1.96 Million |
|
ACCIONA (AJ3.SG)
STU:AJ3
|
$1.96 Million |
|
Your Family Entertainment AG
F:RTV
|
$1.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEMPHASYS LTD's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MEMPHASYS LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MEMPHASYS LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MEMPHASYS LTD's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEMPHASYS LTD (IG7) | €- | N/A | N/A | $1.96 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $16.74 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.74 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $49.08 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.84 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.72 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $592.81 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.80 Million |